News
CDNA
47.40
+1.52%
0.71
High-flyer healthcare stocks: Ten names with strong momentum, weak valuations
Seeking Alpha · 2h ago
Weekly Report: what happened at CDNA last week (0803-0807)?
Weekly Report · 6h ago
CareDx Boardroom Shake-Up: Multiple Directors Quietly Cash Out Millions in Stock
TipRanks · 3d ago
BTIG Remains a Buy on CareDx (CDNA)
TipRanks · 4d ago
CareDx Is Maintained at Buy by BTIG
Dow Jones · 4d ago
CareDx Price Target Raised to $60.00/Share From $45.00 by BTIG
Dow Jones · 4d ago
BTIG Maintains Buy on CareDx, Raises Price Target to $60
Benzinga · 4d ago
CNH Industrial Posts Upbeat Q2 Earnings, Joins Autolus Therapeutics, Bowhead Specialty Holdings And Other Big Stocks Moving Higher On Monday
Benzinga · 08/03 14:00
Craig-Hallum ups CareDx to Buy, says guidance feels conservative
TipRanks · 08/03 11:15
CareDx upgraded to Buy from Hold at Craig-Hallum
TipRanks · 08/03 11:10
Analysts Offer Insights on Healthcare Companies: CareDx (CDNA) and RegenXBio (RGNX)
TipRanks · 08/03 09:30
Weekly Report: what happened at CDNA last week (0727-0731)?
Weekly Report · 08/03 09:17
5 Biotech Stocks That Delivered Big Gains - Key Catalysts Ahead For QURE, CDNA, ADPT, ELVN & AMLX
NASDAQ · 08/02 10:54
CareDx Shares Rise After Raising FY26 Revenue Guidance
Dow Jones · 07/31 17:49
12 Health Care Stocks Moving In Friday's Intraday Session
Benzinga · 07/31 17:05
CareDx jumps on raised 2026 revenue guidance, quarterly beats
Seeking Alpha · 07/31 16:11
At a glance: stocks gapping up premarket
Seeking Alpha · 07/31 12:06
CareDx Price Target Maintained With a $46.00/Share by HC Wainwright & Co.
Dow Jones · 07/31 10:41
HC Wainwright & Co. Reiterates Neutral on CareDx, Maintains $46 Price Target
Benzinga · 07/31 10:31
CareDx boosts outlook after strong Q2 and divestiture
TipRanks · 07/30 21:18
More
Webull provides a variety of real-time CDNA stock news. You can receive the latest news about Caredx through multiple platforms. This information may help you make smarter investment decisions.
About CDNA
CareDx, Inc. is a precision medicine diagnostics company advancing care in transplant, specialty oncology, and cell therapy. Through non-invasive longitudinal molecular biomarker testing, digital health, and patient support solutions, the Company is focused on improving patient outcomes. The Company's integrated solutions include non-invasive molecular testing for heart, kidney, and lung transplants; digital health technologies; and patient solutions that support care before and after transplant. The Company also provides genomic-based information for transplant patients. Its commercially available post-transplant testing services consist of AlloSure Kidney, a donor-derived cell-free DNA, or dd-cfDNA, solution for kidney transplant patients, AlloMap Heart, a gene expression profiling solution for heart transplant patients, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients.